Knopp Biosciences
Pittsburgh, US · Founded 2010 · 2 known investors
Find your way into Knopp Biosciences
Sign up to find every way you can get introduced to Knopp Biosciences
- Your email: who you already know at Knopp Biosciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Knopp Biosciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Knopp Biosciences is a privately held company that manages a portfolio of future milestone payments and product royalties from drug pipelines it sold or spun off in 2022. Its Kv7 small-molecule platform for epilepsy and hyperexcitability disorders was acquired by Biohaven Pharmaceuticals, and its dexpramipexole platform was spun off to Areteia Therapeutics.
Founders & leadership
Knopp Biosciences was founded in 2010 by Thomas V. Petzinger, Jr. and Michael E. Bozik.


Board

Investors · 2
How we know: Saturn Partners's portfolio page · Not right? Tell us
How we know: Solas BioVentures's portfolio page · a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$61.9M disclosed across 6 rounds · 2012–2020
▶$1raisedJan 2021 · 1 investors · BiotechnologyRule 506(b)
- Mark KrestonExecutive Officer
- C. David AdairDirector
- James MatherExecutive Officer
- Calman PrussinExecutive Officer
- Steven DworetzkyExecutive Officer
- Stephen E ButtsDirector
- Jeffrey S. McCormickDirector
- Thomas V. Petzinger Jr.Executive Officer, Director, Promoter
- Gregory T. HebrankExecutive Officer, Director, Promoter
- Michael E. BozikExecutive Officer, Director, Promoter
- Benjamin A. GomezDirector
- Offering amount
- $1
- Amount sold
- $1
- First sale
- Dec 2020
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$12.6MraisedOct 2020 · 24 investors · BiotechnologyRule 506(b)
- Benjamin A. GomezDirector
- James MatherExecutive Officer
- Thomas V. Petzinger, Jr.Executive Officer, Director, Promoter
- Gregory T. HebrankExecutive Officer, Director, Promoter
- C. David AdairDirector
- Stephen E ButtsDirector
- Jeffrey S. McCormickDirector
- Mark KrestonExecutive Officer
- Calman PrussinExecutive Officer
- Steven DworetzkyExecutive Officer
- Michael E. BozikExecutive Officer, Director, Promoter
- Offering amount
- $26M
- Amount sold
- $12.6M
- Sales commissions
- $472.9K
- Proceeds to insiders
- $2.6M
- Placement agents
- Saturn Capital, Inc.
- First sale
- Jun 2020
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$14.9MraisedJun 2020 · 78 investors · BiotechnologyRule 506(b)
- Benjamin A. GomezDirector
- Calman PrussinExecutive Officer
- James MatherExecutive Officer
- Mark KrestonExecutive Officer
- Thomas V. Petzinger, Jr.Director, Promoter
- Jeffrey S. McCormickDirector
- Gregory T. HebrankExecutive Officer, Director, Promoter
- Michael E. BozikExecutive Officer, Director, Promoter
- Steven DworetzkyExecutive Officer
- Offering amount
- $30M
- Amount sold
- $14.9M
- Proceeds to insiders
- $2.5M
- First sale
- Jul 2012
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$1MraisedMar 2020 · 1 investors · BiotechnologyRule 506(b)
- Mark KrestonExecutive Officer
- James MatherExecutive Officer
- Calman PrussinExecutive Officer
- Steve DworetzkyExecutive Officer
- Benjamin A. GomezDirector
- Jeffrey S. McCormickDirector
- Thomas V. Petzinger, Jr.Director, Promoter
- Gregory T. HebrankExecutive Officer, Director, Promoter
- Michael E. BozikExecutive Officer, Director, Promoter
- Offering amount
- $3M
- Amount sold
- $1M
- Proceeds to insiders
- $520K
- First sale
- Mar 2020
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedApr 2015 · 20 investors · BiotechnologyRule 506(b)
- Benjamin A. GomezDirector
- Jeffrey S. McCormickDirector
- Thomas V. Petzinger, Jr.Executive Officer, Director, Promoter
- Gregory T. HebrankExecutive Officer, Director, Promoter
- Michael E. BozikExecutive Officer, Director, Promoter
- Steven DworetzkyExecutive Officer
- Offering amount
- $12.8M
- Amount sold
- $5.4M
- Sales commissions
- $365.2K
- Proceeds to insiders
- $916K
- Placement agents
- Stillpoint Capital, LLC, MIP Global, Inc.
- First sale
- May 2014
- Incorporated
- Limited Liability Company, Delaware, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Knopp Biosciences do?
- Knopp Biosciences is a privately held company that manages a portfolio of future milestone payments and product royalties from drug pipelines it sold or spun off in 2022. Its Kv7 small-molecule platform for epilepsy and hyperexcitability disorders was acquired by Biohaven Pharmaceuticals, and its dexpramipexole platform was spun off to Areteia Therapeutics.
- Who founded Knopp Biosciences?
- Knopp Biosciences was founded by Thomas V. Petzinger, Jr., Michael E. Bozik in 2010.
- Who are Knopp Biosciences's investors?
- Knopp Biosciences's investors include Saturn Partners, Solas BioVentures.
- How much funding has Knopp Biosciences raised?
- Knopp Biosciences has disclosed $61.9M raised across 6 rounds.
- Where is Knopp Biosciences headquartered?
- Knopp Biosciences is headquartered in Pittsburgh, US.
